Endometrial cancer trials in Japan

In Japan 25 Also abroad 395

25 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Where
Akashi, Chūō, Fukuoka, Fukushima, Hidaka, Koto, Kurume, Matsuyama, Nagoya, Niigata, Okayama, Ōta, Sapporo, Shinjuku, Shiwa-gun, Sunto-gun, Tōon, Yamagata
Age
18 years and over
People
1,123 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06952504 · EU 2024-519331-42-00
Phase 1/2Taking people
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Where
Akashi, Fukushima, Hidaka, Koto, Nagaizumi-chō, Ōta, Sapporo, Shinjuku-ku, Yamagata
Age
18 years and over
People
952 worldwide
Run by
Genmab
See details and how to joinNCT05579366
Phase 1Taking people
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Where
Shizuoka, Tokyo
Age
18 years and over
People
575 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06400472 · EU 2024-511238-11-00
Phase 2Taking people
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Where
Chuo Ku, Kashiwa, Koto-ku, Nagoya, Sakai, Sapporo
Age
18 years and over
People
111 worldwide
Run by
Bayer
See details and how to joinNCT06760819 · EU 2024-517419-62-00
Phase 3Taking people
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
Where
Chiba, Fukuoka, Fukushima, Hyōgo, Nagaizumi-chō, Niigata, Osaka, Ōta, Sagamihara-shi, Saitama, Sapporo, Sendai, Shiwa-gun, Takatsuki, Tokyo, Tsu, Yamagata, Yokohama
Age
18 years and over
People
660 worldwide
Run by
Genmab
See details and how to joinNCT07166094
Phase 3Taking people
A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)
Where
Aichi, Fukuoka, Hokkaido, Hyōgo, Kanagawa, Kyoto, Mie, Numakunai, Okayama, Okinawa, Osaka, Saitama, Shizuoka, Tokyo
Age
18 years and over
People
600 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07286331 · EU 2025-523362-25-00
Phase 3Taking people
A Study to Investigate Mocertatug Rezetecan as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02)
Where
Fukuoka, Fukushima, Hokkaido, Ibaraki, Miyagi, Numakunai, Osaka, Saitama, Tokyo
Age
18 years and over
People
610 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07684599 · EU 2025-523363-37-00
Phase 3Taking people
Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer
Where
Akashi, Fukushima, Hidaka, Koto-Ku, Niigata, Sapporo
Age
18 years and over
People
600 worldwide
Run by
Pfizer
See details and how to joinNCT07578649 · EU 2026-525584-40-00
Phase 3Taking people
A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting
Where
Akashi-shi, Chūōku, Fukuoka, Fukushima, Hidaka-shi, Kōtoku, Kurume-shi, Niigata, Okayama, Ota-Shi, Sapporo, Sendai, Shinjuku-ku, Tsu, Yamagata
Age
18 years and over
People
710 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT07022483 · EU 2024-519444-33-00
Phase 2Taking people
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Where
Hidaka, Kagoshima, Kanagawa, Kashiwa-shi, Matsuyama, Nagaizumi-chō, Nagoya, Osakasayama-Shi, Saitama, Tokyo, Yokohama
Age
18 years and over
People
740 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00
Phase 1/2Taking people
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Where
Chuo Ku, Kashiwa, Koto-ku, Matsuyama, Nagaizumi-chō, Nagoya, Ōsaka-sayama, Saitama
Age
18 years and over
People
680 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00
Phase 1/2Taking people
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Where
Chūōku, Hidaka-shi, Kashiwa, Kōtoku, Kurume-shi, Sunto-gun
Age
18 years and over
People
460 worldwide
Run by
AstraZeneca
See details and how to joinNCT05123482 · EU 2022-502759-70-01
Phase 3Taking people
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Where
Akashi-shi, Ginowan-shi, Hidaka-shi, Isehara-shi, Kashiwa, Kashiwa-shi, Kobe, Kōtoku, Kurume-shi, Matsuyama, Morioka, Nagoya, Niigata, Osaka, Ota-shi, Sapporo, Sendai, Shinjuku-ku, Sunto-gun, Tokyo, Yokohama
Age
18 years and over
People
600 worldwide
Run by
AstraZeneca
See details and how to joinNCT06989112 · EU 2023-508056-19-00
Phase 1Taking people
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
Where
Chuo Ku, Hirakata, Kashiwa, Koto-ku
Age
18 years and over
People
234 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06997029 · EU 2025-524334-26-01
Phase 1/2Taking people
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
Where
Hidaka-shi, Kashiwa, Kōtoku, Sunto-gun, Tokyo
Age
18 years to 130 years
People
622 worldwide
Run by
AstraZeneca
See details and how to joinNCT05797168 · EU 2022-502576-23-00
Phase 2Taking people
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Where
Chūōku, Kashiwa, Kōtoku, Nagoya, Shinagawa-ku, Suita-shi
Age
18 years to 130 years
People
454 worldwide
Run by
AstraZeneca
See details and how to joinNCT05489211 · EU 2023-509436-26-00
Phase 1Taking people
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Where
Chūōku
Age
18 years and over
People
540 worldwide
Run by
SystImmune Inc.
See details and how to joinNCT05983432
Phase 1/2Taking people
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
Where
Chiba, Osaka, Tokyo
Age
18 years and over
People
47 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07213609
Phase 1Taking people
A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)
Where
Chiba, Kashiwa, Tokyo, Koto-ku
Age
18 years and over
People
187 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07306559 · EU 2025-522913-45-00
Phase 3Taking people
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
Where
Chūōku, Hidaka-shi, Isehara-shi, Kashiwa-shi, Kōtoku, Kurume-shi, Matsuyama, Minatoku, Nagoya, Nakagami-gun, Niigata, Okayama, Osaka, Sapporo, Sendai, Suita, Sunto-gun, Toon-Shi, Tsu, Yokohama
Age
18 years and over
People
800 worldwide
Run by
AstraZeneca
See details and how to joinNCT07044336 · EU 2024-518777-34-00
Phase 1Taking people
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Where
Kashiwa, Nagaizumi-chō
Age
18 years and over
People
714 worldwide
Run by
Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT05208762 · EU 2023-506604-18-00
Phase 1/2Taking people
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Where
Fukuoka, Hirakata, Kōtō City, Kyoto
Age
18 years and over
People
880 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT05768139 · EU 2023-504807-94-00
Phase 1/2Taking people
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Where
Chuo Ku, Koto-Ku
Age
18 years and over
People
182 worldwide
Run by
Eisai Inc.
See details and how to joinNCT04300556 · EU 2023-506868-14-00
Phase 1/2Taking people
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Where
Chuo Ku, City
Age
18 years and over
People
27 worldwide
Run by
Tanabe Pharma America, Inc.
See details and how to joinNCT06943521
No phaseTaking people
Endometrial Cancer Lymphadenectomy Trial
Where
Okayama, Saitama
Age
18 years to 75 years
People
640 worldwide
Run by
Philipps University Marburg
See details and how to joinNCT03438474